Follow-up data from the CodeBreaK 300 phase III trial compared sotorasib plus panitumumab against standard care in chemorefractory KRAS G12C-mutant CRC, with early findings supporting improved progression-free survival and safety [145]. The gene discussed is KRAS; the disease is colorectal carcinoma.